CAR-T illustration (Shutterstock)

Penn re­searchers find a way through the labyrinth keep­ing CAR-T from sol­id tu­mors

Blood ves­sels are sup­posed to act like trees, pump­ing in oxy­gen tis­sues need to grow and im­mune cells re­quired to clear out pathogens. But in tu­mors, the for­est can go a bit hay­wire. Ves­sels grow prodi­gious­ly and bulge and twist at abrupt points, mak­ing it dif­fi­cult to even tell what’s a vein and what’s an artery. It starts to look less like a for­est and more like a gnarled root floor. “A dis­or­ga­nized labyrinth,” one on­col­o­gist has called it.

For can­cer, chaos is a virtue. That gnarled root floor in­su­lates sol­id tu­mors from im­mune cells and, in re­cent years, has flus­tered drug de­vel­op­ers’ best at­tempts at de­vel­op­ing ther­a­pies meant to rev up the im­mune sys­tem and di­rect it to­ward the tu­mors.

Re­searchers at the Uni­ver­si­ty of Penn­syl­va­nia, how­ev­er, think they may have stum­bled on­to a so­lu­tion, a way of whip­ping the blood ves­sels back in­to prop­er shape. If it works, ex­perts say, it could pave the way for CAR-T treat­ments that at­tack sol­id tu­mors and po­ten­tial­ly im­prove the ef­fec­tive­ness for more tra­di­tion­al ap­proach­es, such as ra­di­a­tion and chemother­a­py.

Patrick Wen

“It’s a re­al­ly nov­el and po­ten­tial­ly im­por­tant ap­proach,” Patrick Wen, a neu­ro-on­col­o­gist at Dana-Far­ber who was not in­volved in the work, told End­points News. “They re­al­ly did good work. This is a very dif­fer­ent way of im­prov­ing im­munother­a­py.” 

Yi Fan, a ra­di­a­tion on­col­o­gist at Penn’s School of Med­i­cine, has been work­ing for the last few years to un­der­stand why the labyrinth ap­pears in the first place. Re­searchers had pre­vi­ous­ly cir­cled in on the so-called growth fac­tors that stim­u­late blood ves­sel for­ma­tion. At­tempts to block these fac­tors, though, dis­ap­point­ed; Avastin, an an­ti­body against the fac­tor VEGF, be­came a block­buster but has con­tin­u­al­ly failed to im­prove sur­vival on a range of ma­lig­nan­cies.

Sci­en­tists would have to go more fun­da­men­tal. In a pair of 2018 pa­pers, Fan showed that part of the prob­lem is a process called “en­dothe­lial cell trans­for­ma­tion.” Cells lin­ing the blood ves­sels around the tu­mor ac­quire stem cell-like prop­er­ties that al­low them to re­pro­duce and ex­pand rapid­ly, as stem cells do.

Yi Fan

“There’s a ge­net­ic re­pro­gram­ming,” Fan told End­points. “They’ll be­come re­al­ly ag­gres­sive.”

But how did that re­pro­gram­ming hap­pen? If Fan could pin down the path­way, he fig­ured he could then de­vise a way to block it. He start­ed knock­ing out ki­nas­es — the cel­lu­lar en­gines that can dri­ve epi­ge­net­ic change, or “re­pro­gram­ming” — one by one in en­dothe­lial cells iso­lat­ed from pa­tients with an ag­gres­sive brain can­cer called glioblas­toma. Out of 518, 35 pre­vent­ed trans­for­ma­tion and one did so par­tic­u­lar­ly well: PAK4.

Then they in­ject­ed tu­mors in­to mice, some who had PAK4 and some who had the ki­nase ge­net­i­cal­ly re­moved: Eighty per­cent of the mice who had PAK4 re­moved lived for 60 days, while all of the wild-type mice died with­in 40. Fan’s team al­so showed that T cells in­fil­trat­ed the tu­mors more eas­i­ly in the PAK4-less mice.

It was a for­tu­itous find­ing: Drug com­pa­nies had de­vel­oped sev­er­al PAK in­hibitors a decade ago, when ki­nase in­hibitors were the flashiest thing in phar­ma. Many had been aban­doned, but Karyopharm had re­cent­ly brought a PAK4 block­er in­to Phase I.

To see whether drug de­vel­op­ers could ex­ploit this find­ing, Fan and his team re­moved T cells from mice and de­vel­oped a CAR-T ther­a­py to at­tack the tu­mors.

They gave mice three dif­fer­ent reg­i­mens. The CAR-T ther­a­py on its own failed to re­duce tu­mor size, ap­par­ent­ly un­able to reach through the ves­sels. The Karyopharm drug al­so had lit­tle ef­fect on its own. But com­bined, they man­aged to re­duce tu­mor size by 80% af­ter five days. They pub­lished the re­sults in Na­ture Can­cer this week.

“It is a re­al­ly eye-open­ing re­sult,” Fan said. “I think we see some­thing re­al­ly dra­mat­ic.”

That, of course, is just in mice, but Fan al­ready has strong sup­port­ing ev­i­dence for PAK4’s role in can­cer. Last De­cem­ber, while Fan was still com­plet­ing his ex­per­i­ment, Na­ture Can­cer pub­lished a pa­per from An­toni Ribas’ UCLA lab sug­gest­ing that PAK4 in­hibitors can help T cells in­fil­trate around var­i­ous sol­id tu­mors. They showed that the same Karyopharm in­hibitor could boost the ef­fects of PD-1 in­hibitors in mice, al­low­ing ac­ti­vat­ed T cells to bet­ter reach tu­mors.

That work has al­ready trans­lat­ed in­to the clin­ic; weeks af­ter it came out, Karyopharm added an arm to their Phase I study of the drug that will look at the PAK4 in­hibitor in com­bi­na­tion with the PD-1 block­er Op­di­vo.

Ribas said that Fan’s work is com­pelling and helps con­firm the role of PAK4, but he said a CAR-T ther­a­py would face a much longer path to the clin­ic. It’s sim­ply much eas­i­er to com­bine an ap­proved drug with an ex­per­i­men­tal one than to de­vise a new CAR-T ther­a­py, mix it with the un­ap­proved in­hibitor (and all the oth­er things, such as bone mar­row-clear­ing chemother­a­py, CAR-T re­cip­i­ents re­ceive) and then de­duce what ef­fect each is hav­ing.

“It will a take a while,” Ribas told End­points. “But I hope this is right and it’s de­vel­oped clin­i­cal­ly.”

There are al­so oth­er un­re­solved ob­sta­cles for CAR-T in sol­id tu­mors, Wen said. De­vel­op­ers still strug­gle to find tar­gets that won’t al­so send the su­per-charged T cells af­ter healthy tis­sue. And tan­gled blood ves­sels are just one of sev­er­al mech­a­nisms tu­mors have of de­fend­ing them­selves. They can, for ex­am­ple, turn tu­mor-eat­ing im­mune cells in­to tu­mor-de­fend­ing ones.

Still, Wen said, in the short term, the ap­proach of­fered a path to­ward boost­ing the ef­fi­ca­cy of ra­di­a­tion, chemother­a­py and oth­er small mol­e­cule drugs. Al­though Fan fo­cused on glioblas­toma, re­searchers agreed PAK4 like­ly plays the same ves­sel-warp­ing role in many oth­er sol­id tu­mors.

“There’s a lot of things you could look at,” he said.

In a Jan­u­ary re­view, Jes­si­ca Fessler and Thomas Gajew­s­ki at the Uni­ver­si­ty of Chica­go said Ribas’ pa­per point­ed to­wards a path for im­prov­ing PD-1 and over­com­ing re­sis­tance in some tu­mors. But they al­so raised ques­tions about the Karyopharm drug, not­ing that it hits oth­er pro­teins be­sides PAK4. That could mean oth­er mech­a­nisms are al­so at play and that the drug could af­fect oth­er tis­sues in hu­mans.

Ribas agreed that Karyopharm’s drug might not be the per­fect mol­e­cule but said oth­ers could be on their way. He serves as a sci­en­tif­ic ad­vi­sor to Ar­cus, the Ter­ry Rosen start­up that is now work­ing on de­vel­op­ing its own PAK4 in­hibitor.

“If they can de­vel­op a very se­lec­tive PAK4 in­hibitor,” he said, “it may be a more di­rect way of test­ing the role of PAK4.”

Tests with that drug, in turn, could help clear up a bi­o­log­i­cal mys­tery that emerged out of Fan’s and Ribas’ pa­pers. Al­though both in­ves­ti­ga­tors ze­roed in on PAK4, each of them sug­gest­ed very dif­fer­ent mech­a­nisms by which PAK4 kept im­mune cells out of the tu­mor. Ribas sug­gest­ed it di­rect­ly sup­press­es T cells, while Fan found it led to those trans­for­ma­tions in­side the blood ves­sels near the tu­mor.

Ki­nas­es are ver­sa­tile pro­teins and both re­searchers said it’s pos­si­ble that PAK4 is do­ing both. It’s al­so pos­si­ble, they said, that one is more im­por­tant than the oth­er, or sim­ply that one of them is just wrong.

“When you start with com­plete­ly new bi­ol­o­gy, it’s hard to get it right the first time,” Ribas said.

Da­ta Lit­er­a­cy: The Foun­da­tion for Mod­ern Tri­al Ex­e­cu­tion

In 2016, the International Council for Harmonisation (ICH) updated their “Guidelines for Good Clinical Practice.” One key shift was a mandate to implement a risk-based quality management system throughout all stages of a clinical trial, and to take a systematic, prioritized, risk-based approach to clinical trial monitoring—on-site monitoring, remote monitoring, or any combination thereof.

Pfiz­er's big block­buster Xel­janz flunks its post-mar­ket­ing safe­ty study, re­new­ing harsh ques­tions for JAK class

When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.

That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

After coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open.

The bloc accused the pharma giant on Wednesday of pulling out of a meeting to discuss cuts to its vaccine supplies, the AP reported. AstraZeneca denied the reports, saying it still planned on attending the discussion.

Early Wednesday, an EU Commission spokeswoman said that “the representative of AstraZeneca had announced this morning, had informed us this morning that their participation is not confirmed, is not happening.” But an AstraZeneca spokesperson later called the reports “not accurate.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Adeno-associated virus-1 illustration; the use of AAVs resurrected the gene therapy field, but companies are now testing the limits of a 20-year-old technology (File photo, Shutterstock)

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

Nicole Paulk was scrolling through her phone in bed early one morning in June when an email from a colleague jolted her awake. It was an article: Two patients in an Audentes gene therapy trial had died, grinding the study to a halt.

Paulk, who runs a gene therapy lab at the University of California, San Francisco, had planned to spend the day listening to talks at the American Association for Cancer Research annual meeting, which was taking place that week. Instead, she skipped the conference, canceled every work call on her calendar and began phoning colleagues across academia and industry, trying to figure out what happened and why. All the while, a single name hung in the back of her head.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pascal Soriot, AP

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

CSL Behring chief Paul Perreault scored an unusual coup last summer when he added AstraZeneca CEO Pascal Soriot to the board, via Zoom. It’s rare, to say the least, to see a Big Pharma CEO take any board post in an industry where interests can simultaneously connect and collide on multiple levels of operations.

The tie set the stage for an important manufacturing connection. The Australian pharma giant agreed to supply the country with 10s of millions of AstraZeneca’s Covid-19 vaccine, once it passes regulatory muster.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mer­ck scraps Covid-19 vac­cine pro­grams af­ter they fail to mea­sure up on ef­fi­ca­cy in an­oth­er ma­jor set­back in the glob­al fight

After turning up late to the vaccine development game in the global fight against Covid-19, Merck is now making a quick exit.

The pharma giant is reporting this morning that it’s decided to drop development of 2 vaccines — V590 and V591 — after taking a look at Phase I data that simply don’t measure up to either the natural immune response seen in people exposed to the virus or the vaccines already on or near the market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Anthony Fauci, NIAID director (AP Images)

As new Covid-19 task force gets un­der­way, threat looms of vac­cine, mon­o­clon­al an­ti­body-re­sis­tant vari­ants

Hours before President Biden’s Covid-19 team gave their first virtual press conference, the famed AIDS researcher David Ho delivered concerning news in a new pre-print: SARS-CoV-2 B.1.351, the variant that emerged in South Africa, is “markedly more resistant” to antibodies from convalescent plasma and vaccinated individuals.

The news for several monoclonal antibodies, including Eli Lilly’s bamlanivimab, was even worse: Their ability to neutralize was “completely or markedly abolished,” Ho wrote. Lilly’s antibody cocktail, which was just shown to dramatically reduce the risk of hospitalizations or death, also became far less potent.

Jackie Fouse, Agios CEO

Agios scores its sec­ond pos­i­tive round of da­ta for its lead pipeline drug — but that won't an­swer the stub­born ques­tions that sur­round this pro­gram

Agios $AGIO bet the farm on its PKR activator drug mitapivat when it recently decided to sell off its pioneering cancer drug Tibsovo and go back to being a development-stage company — for what CEO Jackie Fouse hoped would be a short stretch before they got back into commercialization.

On Tuesday evening, the bellwether biotech flashed more positive topline data — this time from a small group of patients in a single-arm study. And the executive team plans to package this with its earlier positive results from a controlled study to make its case for a quick OK.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Vir's CMO says he's sur­prised that a low dose of their he­pati­tis B drug ap­pears promis­ing in ear­ly slice of da­ta — shares soar

Initial topline data from a Phase I study of a new therapeutic for chronic hepatitis B virus was so promising that it surprised even the CMO of the company that produces it.

Vir Biotechnology on Tuesday announced that its VIR-3434 molecule reduced the level of virus surface antigens present in a blinded patient cohort after eight days of the trial with just a single 6 mg dose. Six of the eight patients in the cohort were given the molecule, and the other two a placebo—all six who received the molecule saw a mean antigen reduction of 1.3 log10 IU/mL, Vir said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.